Hidden RNA Tags May Steer Lung Cancer Growth, Treatment Response, and Survival

Lung cancer remains the deadliest malignancy on the planet, claiming more than 1.8 million lives each year, and even the most advanced targeted drugs and immunotherapies leave patients with advanced disease facing a five-year survival rate of just seven percent. Now a comprehensive review published in Holistic Integrative Oncology argues that a chemical tag on RNA molecules, invisible to the genome itself, may hold some of the missing answers. The modification, known as N6-methyladenosine or m6A, is the most abundant internal chemical mark found on messenger RNA in eukaryotic cells, and researchers led by Shufan Liang and Chengdi Wang of West China Hospital, Sichuan University, have assembled the strongest case yet that this epitranscriptomic layer shapes nearly every aspect of lung cancer biology, from the first malignant transformation to the failure of frontline therapies.

The mechanics of m6A are elegant. The tag is deposited on RNA by a methyltransferase complex whose catalytic core is the enzyme METTL3, working alongside METTL14, which recognizes the target sequence, and the scaffolding proteins WTAP and RBM15, which shepherd the machinery to specific sites on transcripts. The marks cluster near stop codons and within three-prime untranslated regions, precisely where they can influence how efficiently a message is translated into protein or how quickly it is degraded. Demethylases such as FTO and ALKBH5 can remove the marks, although recent evidence questioning whether FTO truly reverses m6A in vivo suggests the system may be more nuanced than a simple write-and-erase cycle. Once installed, the tags are interpreted by reader proteins, most carrying a conserved YTH domain, that determine the fate of each modified transcript, directing splicing in the nucleus, export to the cytoplasm, ribosome loading, or routing to processing bodies for destruction.

What makes m6A so compelling in oncology is its contextual duality. In lung adenocarcinoma cells, METTL3 was found to be elevated, where it stabilized the mRNA of SLC7A11, a ferroptosis-suppressing transporter, thereby blocking iron-dependent cell death and fueling proliferation. Yet when the tumor suppressor p53 is intact, the very same enzyme amplifies p53 stress responses and suppresses cellular transformation, a finding that highlights how the same molecular writer can act as villain or guardian depending on the genetic backdrop. The demethylase ALKBH5 shows similar ambivalence: it promotes proliferation in non-small cell lung cancer by destabilizing genes such as TIMP3 and CDKN1A, but a specific regulatory insertion variant that boosts ALKBH5 expression was found to suppress tumor growth through the ALKBH5-FBXL5 axis, inhibiting the PI3K/AKT and NF-kB pathways.

Environmental carcinogens appear to hijack this system. Chronic exposure to hexavalent chromium, an industrial pollutant, upregulated METTL3 and drove cell transformation, cancer stem cell-like properties, and spontaneous lung tumors in experimental models. The tobacco-specific nitrosamine NNK, meanwhile, triggered malignant transformation of bronchial epithelial cells through the reader protein IGF2BP1, which correlated with shorter overall survival and metastatic spread, while ALKBH5-mediated demethylation of COL5A1 promoted NNK-induced proliferation that could be reversed when the eraser was knocked down. These findings suggest that the epitranscriptome is not merely a passenger in carcinogenesis but a mechanistic conduit through which the environment rewrites cellular behavior.

Invasion and metastasis, the processes that make lung cancer lethal, are also under m6A control. METTL3 enhances the translation of EGFR mRNA by recruiting the initiation factor eIF3 and promotes motility through EML4, while its induction of the long noncoding RNA LCAT3 activates the MYC oncogene via the binding protein FUBP1. The writer VIRMA suppresses the kinase DAPK3 through YTHDF2- and YTHDF3-mediated inhibition, releasing the brakes on migration, and FTO drives metastasis by elevating fibroblast activation protein in a YTHDF2-dependent manner. Angiogenesis, the sprouting of blood vessels that feeds growing tumors, is accelerated when m6A marks on the VEGFA internal ribosome entry site recruit the YTHDC2/eIF4GI complex to boost translation, and IGF2BP2 shuttled from tumor cells to endothelial cells activates PI3K-Akt signaling to promote vessel formation. The reader IGF2BP3, through its MCM5/Notch and STRIP2/TMBIM6 axes, drives the epithelial-mesenchymal transition that converts stationary epithelial cells into mobile, invasive ones.

Perhaps the most clinically electrifying chapter concerns therapy. In immunotherapy, METTL3 promotes the circularization of circIGF2BP3, which reduces CD8-positive T cell infiltration and undermines anti-PD-1 efficacy, while its suppression lifts hsa-LINC02418, a transcript that enhances PD-L1 ubiquitination via Trim21. Two METTL3 inhibitors are already in human testing: STC-15 showed well-tolerated responses in a phase 1 trial of advanced cancers, and a multicenter phase 1b/2 trial is now combining it with the anti-PD-1 antibody toripalimab. The second inhibitor, STM2457, reprogrammed the tumor microenvironment into a more inflamed state, rendering anti-PD-1 therapy more effective in preclinical models. Conversely, ALKBH5 increased susceptibility to immunotherapy by recruiting PD-L1-positive tumor cells and macrophages through CCL2 and CXCL10 secretion, and a five-regulator m6A score predicted anti-PD-1 benefit with an area under the curve of 0.8.

Drug resistance, the Achilles heel of targeted therapy, is likewise epitranscriptomically scripted. The writer KIAA1429, overexpressed in gefitinib-resistant tumors, stabilizes HOXA1 mRNA and activates JNK/MAPK signaling, while FTO delivered in serum exosomes boosts the drug efflux pump ABCC10 through YTHDF2, pumping gefitinib out of cells. An IGF2BP3-COX6B2 axis rewires nicotinamide metabolism toward oxidative phosphorylation to confer acquired resistance, and YTHDF2 with METTL3 degrade TUSC7 and cLMNB1 to drive erlotinib and osimertinib resistance respectively. In chemotherapy, KRAS-mutant tumors inhibit ALKBH5, hypermethylating the DNA repair genes DDB2 and XPC to survive platinum agents, while IGF2BP-stabilized SNRPA builds the ERCC1-XPF repair complex. In small cell lung cancer, METTL3 accelerates DCP2 degradation and mitophagy to produce chemoresistance, a phenotype that STM2457 could reverse. Even radiotherapy is affected: IGF2BP2 and METTL3 both promote radioresistance through a methionine-transport feedback loop and RMRP-stabilized stemness, respectively.

Beyond treatment, m6A regulators are emerging as prognostic instruments. Individual markers tell mixed stories: high ALKBH5 and IGF2BP1 worsen survival, while deletions of FTO and YTHDC2 predict better disease-free survival, and higher YTHDF1 and YTHDF2 levels associate with improved overall and recurrence-free survival. Combination models perform better still. A three-gene risk score built from METTL3, KIAA1429, and IGF2BP1 stratified non-small cell lung cancer patients by survival and correlated with smoking history and stage, and a PD-L1-linked prognostic model achieved an area under the curve of 0.746. In small cell lung cancer, a seven-regulator LASSO Cox model predicted chemotherapy benefit with a striking area under the curve of 0.935, while three distinct m6A modification patterns, corresponding to immune activation, immune escape, and immune desert, mapped the tumor microenvironment and identified patients likely to respond to immunotherapy.

The review’s authors are candid about the obstacles ahead. The same regulator can show opposite effects in different studies, as the METTL3 paradox illustrates, underscoring the heterogeneity of m6A biology across pathological subtypes and p53 statuses. Diagnostic applications remain scarce, most single-molecule prognostic markers have not been quantified rigorously, and combination models still show only moderate performance. Druggability poses its own challenge: ideal targets require spatial conformations amenable to small-molecule binding, and conserved or closed structures risk off-target effects and poor pharmacokinetics. Yet the trajectory is unmistakable. With clinical trials of METTL3 inhibitors underway, liquid biopsy offering a non-invasive route to detect m6A signatures, and multi-dimensional models integrating epitranscriptomic data with radiological and clinicopathological features, the humble methyl tag on adenosine is rapidly moving from bench curiosity to a potential linchpin of precision oncology, one RNA molecule at a time.

Subject of Research: The role of N6-methyladenosine RNA modification in lung cancer progression, treatment regulation, and prognosis prediction

Article Title: Role of N6-methyladenosine in the progression, treatment regulation, and prognosis prediction of lung cancer

Article References: Liang, S., Shao, J., Li, J., Liu, X., Yang, L., Li, W., & Wang, C. (2026). Role of N6-methyladenosine in the progression, treatment regulation, and prognosis prediction of lung cancer. Holistic Integrative Oncology, 5(1), Article 47. https://doi.org/10.1007/s44178-026-00259-8

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00259-8

Keywords: N6-methyladenosine, m6A, lung cancer, RNA modification, epitranscriptomics, METTL3, immunotherapy, drug resistance, prognosis, biomarkers, non-small cell lung cancer, targeted therapy